Ready to play
Ready to play
China relies heavily on imported human albumin, primarily sourced from US plasma donors, which accounts for about 70% of its supply. This reliance poses risks of shortages and price increases amid geopolitical tensions or global crises. Despite efforts to boost domestic plasma collection and develop alternative sources like rice-derived albumin, China continues to face a significant shortfall, reflecting the ongoing legacy of past safety concerns and regulatory challenges.
Notice: This Is an AI-Generated Summary
Comments (0)